Grail taps Genentech vet Jennifer Cook as CEO, building expectations for 2018
After a curious series of C-suite departures, Silicon Valley’s Grail has locked in on someone whom it trusts to lead the cancer detection biotech into commercial operations: Jennifer Cook. Cook replaces interim CEO Bill Rastetter, the Illumina advisor who stepped in after founding CEO Jeff Huber resigned in August.
If her resume is any indication, Cook is here to stay. An early devotee to biotech, she has worked at Genentech pretty much her whole career (minus a four-year stint at a startup early on), joining in 1987 and moving to Roche in 2013, after Genentech had become a subsidiary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.